The Alzheimer Disease Research Center (ADRC) at the University of Southern California (USC) focuses on Reducing Alzheimer and Vascular Contributions to Cognitive Impairment in Diverse Populations. The ADRC views brain health in the broad context of the neurobiology and psychology of aging, with Alzheimer Disease (AD) and cerebrovascular disease (CVD) as the two major causes of pathological cognitive decline. We have built an interdisciplinary team to bridge basic science to clinical trials, well before the term "translational" research became popular. This renewal application includes three projects which strengthen translational research. Our populations include a 15-year prospective study of Caucasians enrolled in the Long Beach Longitudinal Study (LBLS), a 10-year prospective study of Hispanics in the community-based Los Angeles Latino Eye Study (LALES) and a newly funded, community-based Chinese American Eye Study (CHES). Several affiliated cohorts include the Aging Brain Program Project (PLChui) and the Progesterone and Brain Aging and Alzheimer Disease (PI: R. Brinton). During the next five years, we will focus on the following overarching goals: 1) Clarify the pathological and phenotypic interactions between AD and CVD, 2) Increase recruitment and retention of minority subjects from LALES, CHES, and the surrounding neighborhood, 3) Promote clinical trials and translational research in memory and aging at USC, and 4) Continue active participation in national initiatives, including National Alzheimer Coordinating Center (NACC), Alzheimer Disease Cooperative Study (ADCS), Alzheimer Disease Neuroimaging Initiative (ADNI), and Genome Wide Association Study (GWAS). The ADRC comprise 6 Cores (Administration, Data, Clinical, Education, Pathology, and Imaging) and 3 Projects: Zelinski (Course of Cognitive Change in Late Adulthood), Brinton/Pike (Novel NeuroSERMs and NeuroSARMs for protection against Alzheimer pathology), and Zheng (Cognitive Impairment in a Chinese American Community).

Public Health Relevance

Alzheimer and cerebrovascular disease are the two most important threats to cognitive health in aging. Epidemiologic studies indicate that vascular risks factors increase the risk of AD. Many vascular risk factors are eminently treatable. Reduction of vascular risk factors would decrease the risk of cognitive decline.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005142-29
Application #
8450802
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J2))
Program Officer
Phelps, Creighton H
Project Start
1997-04-15
Project End
2015-03-31
Budget Start
2013-06-01
Budget End
2014-03-31
Support Year
29
Fiscal Year
2013
Total Cost
$1,984,522
Indirect Cost
$778,338
Name
University of Southern California
Department
Neurology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Schneider, L S; Mangialasche, F; Andreasen, N et al. (2014) Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 275:251-83
Gatto, Nicole M; Henderson, Victor W; Hodis, Howard N et al. (2014) Components of air pollution and cognitive function in middle-aged and older adults in Los Angeles. Neurotoxicology 40:1-7
Finch, Caleb E; Beltrán-Sánchez, Hiram; Crimmins, Eileen M (2014) Uneven futures of human lifespans: reckonings from Gompertz mortality rates, climate change, and air pollution. Gerontology 60:183-8
Villeneuve, Sylvia; Reed, Bruce R; Wirth, Miranka et al. (2014) Cortical thickness mediates the effect of ?-amyloid on episodic memory. Neurology 82:761-7
Porsteinsson, Anton P; Drye, Lea T; Pollock, Bruce G et al. (2014) Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311:682-91
Beecham, Gary W; Hamilton, Kara; Naj, Adam C et al. (2014) Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. PLoS Genet 10:e1004606
Schneider, Lon S (2014) Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimers Dement 10:247-50
Escott-Price, Valentina; Bellenguez, Céline; Wang, Li-San et al. (2014) Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. PLoS One 9:e94661
Cuajungco, Math P; Basilio, Luigi C; Silva, Joshua et al. (2014) Cellular zinc levels are modulated by TRPML1-TMEM163 interaction. Traffic 15:1247-65
Jayaraman, Anusha; Christensen, Amy; Moser, V Alexandra et al. (2014) Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology 155:1398-406

Showing the most recent 10 out of 253 publications